CENTEK(SZ:000931) Xin Lang Cai Jing·2025-12-12 08:13Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Four Ring Pharmaceutical, has had several of its products included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025), which may influence future sales but will not significantly impact the company's current operating performance [1] Group 1: Product Inclusion - A total of 34 products from the company's subsidiaries, including Beijing Huasu, Shandong Huasu, and Duoduo Pharmaceutical, have been included in the 2025 drug catalog [1] - New products added to the catalog include Sulfate Fish Protein Injection and Compound Pancreatin Powder [1] - Products previously included in the 2024 catalog, such as Bisoprolol Fumarate Tablets and Benidipine Hydrochloride Tablets, will continue to be listed [1] Group 2: Product Changes - Beijing Huasu's "Compound Chlorphentermine Injection" has been removed from the 2025 catalog [1] - Duoduo Pharmaceutical's "Ambroxol Hydrochloride Injection" has been newly included in the catalog [1] Group 3: Market Impact - The future sales of the included products may be affected by changes in the market environment and other factors [1] - The company states that these changes will not have a major impact on its current operating performance [1]